Loading
Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades.
Rossella Elisei is professor of endocrinology at the University of Pisa, one of the largest thyroid cancer centres in Europe. She was first author of the 2013 Journal of Clinical Oncology report of EXAM, the phase 3 trial in which cabozantinib lengthened progression-free survival compared with placebo in progressive metastatic medullary thyroid cancer, leading to its approval. Her research covers the prognostic value of RET mutations and calcitonin doubling time.
| Title | Journal | Year |
|---|---|---|
| EXAM: cabozantinib in progressive medullary thyroid cancer | Journal of Clinical Oncology | 2013 |
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.
Shares the tags targeted-therapy, trialist.